CARE's contrastive multi-agent adjudication lifts zero-shot melanoma-vs-atypical-nevus accuracy from 66.5% to 77.6%, but still trails Gemini-3-Pro on chest X-rays
In a zero-shot, training-free, tool-free setting, the authors benchmark multimodal LLM agents on two imaging-only proxy tasks (melanoma vs. atypical nevus and pulmonary edema vs. pneumonia) and propose CARE, a multi-agent framework in which two disease-specific agents generate opposing evidence and a third judge adjudicates it against the original image; CARE raises Gemini-3-Flash accuracy from 66.5% to 77.6% (Youden 0.552) on dermoscopy and from 60.2% to 64.6% on chest X-rays, yet remains below Gemini-3-Pro's 70.9% on the chest task and overall below clinical deployment requirements.